Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.

There are two main types of skin cancer; Non-melanoma skin cancer and melanoma. Non-melanoma skin cancer, which slowly ...

Squamous cell carcinoma is the second most common type of skin cancer, and can be deadly if left untreated. Here are the ...

PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

REHOVOT, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: ...

We are thrilled to share that the first trial site has been initiated and activation of additional clinical sites continues,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including ...

In a small study in a community oncology practice, more than 60% of patients with advanced squamous cell skin cancer treated ...